The Problems and the Promise of Prostaglandin Influences in Atherogenesis
- 1 October 1985
- journal article
- review article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 454 (1) , 121-130
- https://doi.org/10.1111/j.1749-6632.1985.tb11850.x
Abstract
No abstract availableKeywords
This publication has 78 references indexed in Scilit:
- Human plasma transforms prostacyclin (PGI2) into a platelet antiaggregatory substance which contracts isolated bovine coronary arteriesProstaglandins, 1980
- Topical prostacyclin (PGI2) inhibits platelet aggregation in pial venules of the mouse.Stroke, 1979
- ANTI‐AGGREGATORY EFFECT OF PROSTACYCLIN (PGI2) in vivoBritish Journal of Pharmacology, 1979
- Prevention of blockage of partially obstructed coronary arteries with prostacyclin correlates with inhibition of platelet aggregationProstaglandins, 1979
- RECIRCULATION OF PROSTACYCLIN (PGI2) IN THE DOGBritish Journal of Pharmacology, 1978
- Circulatory and anti-platelet effects of intravenous prostacyclin in healthy menPharmacological Research Communications, 1978
- Localisation and stimulation of prostacyclin production in vascular cellsNature, 1978
- Synthesis of prostaglandin I2 (prostacyclin) by cultured human and bovine endothelial cells.Proceedings of the National Academy of Sciences, 1977
- Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endotheliumThrombosis Research, 1977
- An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregationNature, 1976